MARKET

KRON

KRON

Kronos Bio, Inc.
NASDAQ
1.300
+0.060
+4.84%
After Hours: 1.340 +0.04 +3.08% 19:14 03/28 EDT
OPEN
1.260
PREV CLOSE
1.240
HIGH
1.350
LOW
1.210
VOLUME
312.67K
TURNOVER
0
52 WEEK HIGH
2.290
52 WEEK LOW
0.7310
MARKET CAP
78.12M
P/E (TTM)
-0.6662
1D
5D
1M
3M
1Y
5Y
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 1d ago
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
TipRanks · 3d ago
Weekly Report: what happened at KRON last week (0318-0322)?
Weekly Report · 4d ago
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
TipRanks · 03/22 06:01
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
Kronos Bio reported earnings per share of -43 cents for the fourth quarter of 2023. The company reported revenue of $2.29 million. This was 50.39% better than the analyst estimate for revenue. Kronos Bio is a biotechnology company.
Investorplace · 03/21 17:53
Kronos Bio reports Q4 results
Seeking Alpha · 03/21 16:41
Recap: Kronos Bio Q4 Earnings
Kronos Bio reported its Q4 earnings on March 21. Kronos Bio beat estimates by 17.0%. The company's revenue was up $2.29 million from the same period last year. The company is expected to announce its earnings Thursday morning. Last quarter the company missed on EPS by $0.03.
Benzinga · 03/21 13:35
Kronos Bio Inc reports results for the quarter ended in December - Earnings Summary
Kronos Bio Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 34 cents per share. Revenue was $2.29 million; analysts expected $1.53 million. Kronos Bio shares had fallen by 3.2% this quarter.
Reuters · 03/21 12:38
More
About KRON
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Webull offers Kronos Bio Inc stock information, including NASDAQ: KRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KRON stock methods without spending real money on the virtual paper trading platform.